 <h1>Jynarque Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>tolvaptan</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about tolvaptan. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Jynarque.</p><h2>In Summary</h2><p><b>Common side effects of Jynarque include:</b> polyuria, increased thirst, pollakiuria, and xerostomia. <b>Other side effects include:</b> constipation, fever, hyperglycemia, increased serum alanine aminotransferase, and anorexia.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to tolvaptan: oral tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Samsca速 should be initiated and re-initiated in patients only in a hospital where serum sodium can be monitored closely. Too-rapid correction of hyponatremia (eg, greater than 12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma, and death. Slower rates of correction may be advisable in susceptible patients (eg, those with severe malnutrition, alcoholism, or advanced liver disease).Samsca速 Not For Use For Autosomal Dominant Polycystic Kidney Disease (ADPKD): Because of the risk of hepatoxicity, tolvaptan should not be used for ADPKD outside of the FDA-approved REMS.</p><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Warning: Risk Of Serious Liver Injury:Jynarque(TM) (tolvaptan) can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported.Measure ALT, AST and bilirubin before initiating treatment, at 2 weeks and 4 weeks after initiation, then monthly for the first 18 months and every 3 months thereafter. Prompt action in response to laboratory abnormalities, signs, or symptoms indicative of hepatic injury can mitigate, but not eliminate, the risk of serious hepatotoxicity.Because of the risks of serious liver injury, Jynarque(TM) is available only through a restricted distribution program under a Risk Evaluation and Mitigation Strategy (REMS) called the Jynarque(TM) REMS Program.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, tolvaptan (the active ingredient contained in Jynarque) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking tolvaptan:</p><p>
<i>More common</i>
</p><ul>
<li>Blurred vision</li>
<li>dry mouth</li>
<li>flushed, dry skin</li>
<li>frequent urination</li>
<li>fruit-like breath odor</li>
<li>increased hunger</li>
<li>increased thirst</li>
<li>increased urination</li>
<li>increased volume of pale, dilute urine</li>
<li>nausea</li>
<li>stomach pain</li>
<li>sweating</li>
<li>thirst</li>
<li>troubled breathing</li>
<li>unexplained weight loss</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Anxiety</li>
<li>blood in the urine</li>
<li>bloody stools</li>
<li>blue lips, fingernails, or skin</li>
<li>bruising</li>
<li>chest pain</li>
<li>confusion</li>
<li>cough</li>
<li>coughing or vomiting blood</li>
<li>dark urine</li>
<li>dizziness or lightheadedness</li>
<li>fainting</li>
<li>fast, slow, irregular, or shallow heartbeat</li>
<li>fever</li>
<li>irregular, fast or slow, or shallow breathing</li>
<li>loss of consciousness</li>
<li>muscle cramp, spasm, pain, or stiffness</li>
<li>pain, redness, or swelling in the arm or leg</li>
<li>persistent bleeding or oozing from puncture sites, mouth, or nose</li>
<li>pink or red urine</li>
<li>rash</li>
<li>rectal bleeding</li>
<li>stomach tenderness</li>
<li>troubled breathing</li>
<li>sweating</li>
<li>vaginal bleeding</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Difficulty swallowing</li>
<li>general feeling of tiredness or weakness</li>
<li>headache</li>
<li>high blood pressure</li>
<li>hives, itching, skin rash</li>
<li>irritability</li>
<li>light-colored stools</li>
<li>muscle twitching</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>restlessness</li>
<li>seizures</li>
<li>stomach pain, continuing</li>
<li>swelling of the feet or lower legs</li>
<li>tightness in the chest</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of tolvaptan may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Difficulty having a bowel movement</li>
<li>lack or loss of strength</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Loss of appetite</li>
<li>weight loss</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to tolvaptan: oral kit, oral tablet</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Intracardiac thrombus, ventricular fibrillation, orthostatic hypotension<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Dry mouth (up to 13%), nausea</p>
<p><b>Common</b> (1% to 10%): Constipation, ischemic colitis, gastrointestinal bleeding, diarrhea<sup>[Ref]</sup></p><h3>General</h3><p>The most frequently reported side effects included thirst, dry mouth (up to 13%), asthenia, constipation, pollakiuria or polyuria and hyperglycemia.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Blood in urine</p>
<p><b>Uncommon</b> (0.1% to 1%): Urethral hemorrhage, vaginal hemorrhage<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Prolonged prothrombin time, disseminated intravascular coagulation<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Rhabdomyolysis</p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Cerebrovascular accident, syncope, dizziness, headache</p>
<p><b>Uncommon</b> (0.1% to 1%): Dysgeusia</p>
<p><b>Postmarketing reports</b>: Osmotic demyelination syndrome<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Pollakiuria and polyuria (11%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Renal impairment<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pulmonary embolism, respiratory failure<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hyperglycemia, anorexia, diabetic ketoacidosis, dehydration, hyperkalemia, decreased appetite, creatinine increased, hypernatremia, hypoglycemia, hyperuricemia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Ecchymosis, pruritus</p>
<p><b>Uncommon</b> (0.1% to 1%): Pruritic rash<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b>: Alanine aminotransferase increased, aspartate aminotransferase increased, bilirubin increased</p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Hypersensitivity reactions including anaphylactic shock and generalized rash</p><h3>Other</h3><p><b>Very common</b> (10% or more): Thirst (up to 18%)</p>
<p><b>Common</b> (1% to 10%): Asthenia, pyrexia, malaise</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Samsca (tolvaptan)." Otsuka American Pharmaceuticals Inc, Rockville, MD. </p><p id="ref_2">2. Gerlo S,  Verdood P,  Kooijman R "Tumor necrosis factor-alpha activates the extrapituitary PRL promoter in myeloid leukemic cells." J Neuroimmunol 172(1-2) (2006): 206-10</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What is the difference between Jynarque (tolvaptan) and Samsca (tolvaptan)?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Jynarque (tolvaptan)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa単ol</li>
<li>FDA Alerts (2)</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Jynarque &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Samsca</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to tolvaptan: oral kit, oral tablet</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Intracardiac thrombus, ventricular fibrillation, orthostatic hypotension<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Dry mouth (up to 13%), nausea</p><p><b>Common</b> (1% to 10%): Constipation, ischemic colitis, gastrointestinal bleeding, diarrhea<sup>[Ref]</sup></p><h3>General</h3><p>The most frequently reported side effects included thirst, dry mouth (up to 13%), asthenia, constipation, pollakiuria or polyuria and hyperglycemia.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Blood in urine</p><p><b>Uncommon</b> (0.1% to 1%): Urethral hemorrhage, vaginal hemorrhage<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Prolonged prothrombin time, disseminated intravascular coagulation<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Rhabdomyolysis</p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Cerebrovascular accident, syncope, dizziness, headache</p><p><b>Uncommon</b> (0.1% to 1%): Dysgeusia</p><p><b>Postmarketing reports</b>: Osmotic demyelination syndrome<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Pollakiuria and polyuria (11%)</p><p><b>Uncommon</b> (0.1% to 1%): Renal impairment<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pulmonary embolism, respiratory failure<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hyperglycemia, anorexia, diabetic ketoacidosis, dehydration, hyperkalemia, decreased appetite, creatinine increased, hypernatremia, hypoglycemia, hyperuricemia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Ecchymosis, pruritus</p><p><b>Uncommon</b> (0.1% to 1%): Pruritic rash<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b>: Alanine aminotransferase increased, aspartate aminotransferase increased, bilirubin increased</p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Hypersensitivity reactions including anaphylactic shock and generalized rash</p><h3>Other</h3><p><b>Very common</b> (10% or more): Thirst (up to 18%)</p><p><b>Common</b> (1% to 10%): Asthenia, pyrexia, malaise</p><p id="ref_1">1. "Product Information. Samsca (tolvaptan)." Otsuka American Pharmaceuticals Inc, Rockville, MD. </p><p id="ref_2">2. Gerlo S,  Verdood P,  Kooijman R "Tumor necrosis factor-alpha activates the extrapituitary PRL promoter in myeloid leukemic cells." J Neuroimmunol 172(1-2) (2006): 206-10</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What is the difference between Jynarque (tolvaptan) and Samsca (tolvaptan)?</li>
</ul><h2>More about Jynarque (tolvaptan)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa単ol</li>
<li>FDA Alerts (2)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Jynarque &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>